Skip to search formSkip to main contentSkip to account menu

6 ML RADIUM CHLORIDE RA-223 30 MCI/ML Injection [Xofigo]

Known as: Xofigo 1100 kBq/ML in 6 ML Injection, Xofigo (radium Ra-223 dichloride) 6600 kBq per 6 ML Injection, RADIUM RA-223 DICHLORIDE 30 uCi in 1 mL INTRAVENOUS INJECTION [Xofigo] 
National Institutes of Health

Related topics

Related topics

9 relations

Broader (2)

6 ML RADIUM CHLORIDE RA-223 30 MCI/ML InjectionRADIUM CHLORIDE RA-223 Injection [Xofigo]
Hydrochloric AcidInjectionRADIUM CHLORIDE RA-223Sodium Chloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Radiopharmacy/Radiochemistry for Conventional Single-Photon Emitting and Therapeutic Radiopharmaceuticals
Conventional agents for diagnostic single-photon emission imaging and for radionuclide therapy are mostly associated with… 
2018
2018
Alphatherapy, the new impetus to targeted radionuclide therapy?
Review
2017
Review
2017
Radium 223 dichloride for prostate cancer treatment
Prostate cancer is the most common malignant disease in men. Several therapeutic agents have been approved during the last 10… 
2017
2017
Abstract 836: ATR inhibitor BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride in preclinical tumor…
The integrity of the genome of eukaryotic cells is secured by complex signaling pathways, known as DNA damage response (DDR… 
Review
2017
Review
2017
Alpharadin-Therapie bei Patienten mit metastasiertem kastrationsrefraktärem Prostatakarzinom
ZusammenfassungAlpharadin (223Radiumdichlorid/Xofigo®) ist ein seit November 2013 zur Therapie des fortgeschrittenen… 
Review
2015
Review
2015
Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature
Objectives: Prostate cancer (PC) is the most common cancer in Western countries. Recent advances in the treatment of metastatic… 
2015
2015
Nuclear medicine and the revolution in the modern management of castration-resistant prostate cancer patients: from 223Ra-dichloride to new horizons for therapeutic response assessment
Prostate cancer (PC) is the most common neoplasm in men in Western countries, and approximately 10 – 20 % of patients with PC… 
2015
2015
Anvisa aprova radiofármaco xofigo
A Anvisa aprovou o Xofigo® (radium 223) , para o tratamento de pacientes com câncer de prostata resistente a castracao (CPRC… 
2014
2014
Radium-223 dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease
In patients with advanced castration-resistant prostate cancer (CRPC), symptomatic bone metastases are frequently present. Xofigo… 
2014
2014
Radiothérapie interne par dichlorure de radium 223 (Xofigo®) : comment faisons-nous en pratique ?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)